Bladder Cancer News Archive
The 5-year overall survival rate is significantly higher among radical cystectomy patients who receive neoadjuvant vs adjuvant chemotherapy, study finds.
Daily use of aspirin before radical cystectomy is associated with a significant 36% and 30% decreased risk of cancer-specific and all-cause mortality.
A study found that bladder cancer and UTUC occurred in 122.22 and 113.97 per 100,000 persons per year, respectively, among kidney transplant recipients.
Positive results before BCG treatment and at the 6-week instillation are associated with an increased likelihood of disease recurrence and/or progression.
Female sex and need for a blood transfusion are associated with development of Clostridium difficile infection following radical cystectomy.
Large study reveals a significant 15% survival advantage associated with radical cystectomy vs chemoradiation therapy.
Enhanced therapeutic effect of bacillus Calmette-Gurin tx in non-muscle invasive bladder cancer.
Men and women who smoke are at 2.3-fold and 2.7-fold increased risk of bladder cancer compared with non-smokers.
Instilling gemcitabine into the bladder immediately following resection of low-grade non-muscle-invasive bladder cancer significantly lowers recurrence risk.
One-year overall survival of 61% for gemcitabine and cisplatin plus ipilimumab.
When combined with cytology, UroSEEK detected 95% of patients who developed bladder cancer
Use of 5-alpha-reductase inhibitors before and after diagnosis of the malignancy is associated with a 15% and 22% decreased risk of bladder cancer mortality, respectively.
In multivariable analyses, CKD stage G3b or higher was significantly associated with worse progression-free and cancer-specific survival.
Model, based on 6 factors, predicts overall survival for patients treated with atezolizumab
Appears to be a cost-effective strategy for patients with small size, stage pTa or pT1a recurrent tumors
In a 3-year study, toxic effects of atezolizumab remained manageable and responses durable.
Study results serve as a caution against relying on ureteroscopic biopsy to establish tumor grade and stage, researchers say.
Patients with bladder adenocarcinomas have the best survival, whereas those with small cell carcinomas of the bladder have the worst.
In a study, nearly 20% of radical cystectomy patients were readmitted for complications within 90 days compared with 1.9% and 5.9% for radical prostatectomy and radical nephrectomy, respectively.
Nicotine and nicotine-derived nitrosamine ketone enhance mutational susceptibility in human cells.
A Charlson Comorbidity Index score of 2 or higher is an independent risk factor for urinary tract infections within 90 days following radical cystectomy for bladder cancer, study finds.
Diffusion-weighted imaging and use of higher field strengths further improve accuracy.
The locoregional recurrence-free survival rate at 2 years was significantly higher for patients treated with chemotherapy plus RT versus those treated with chemotherapy alone.
Patients on hemodialysis who undergo radical cystectomy for bladder cancer have 30-day and 5-year mortality rates of 9.3% and 87.9%, respectively, study finds.
Patients with versus without a history of urinary calculi had nearly 2-fold greater odds of bladder cancer, meta-analysis showed.
40% of active surveillance events were deemed to require treatment.
Chemoradiation for muscle-invasive bladder cancer is associated with a lower 1-year mortality risk versus radical cystectomy, but at year 2 and beyond, mortality risk is lower with radical cystectomy.
No evidence that varenicline, bupropion, or nicotine replacement increase probability of abstinence.
Durable survival, response rates rarely recognized as significant by current oncology value frameworks.
Most patients with cancer, autoimmune disease have improvement in events without discontinuing therapy.
The proportion of patients who received neoadjuvant chemotherapy for muscle-invasive bladder cancer prior to cystectomy rose from 4% to 27% of patients from 1994 to 2013.
A feasibility study involving 60 patients with bladder cancer sought to determine if preoperative vigorous cardiovascular activity would improve postsurgical outcomes.
About 45.1% of cancer deaths and 42% of all incident cancers are linked to modifiable risk factors.
Mean disease-specific survival at 10 years was 50.9% for TMT and 57.8% for RC patients, a non-significant difference.
Reduction occurred after implementation of EPA's maximum contaminant level for arsenic
General practitioners less likely to support smoking cessation in patients with cancer than with CHD
FDA has accepted a supplemental New Drug Application asking to expand the labeling indication for Cysview to include use the bladder cancer-detecting system in the outpatient setting.
Tool incorporates the relative contribution of tumor stage, lymph node involvement.
Patients with high alteration number in variants of unknown significance had better outcomes.
Patients on combination therapy have increased risk of thyroid dysfunction and hypophysitis.
The researchers note that TACC3 is a mitotic spindle protein required for accurate segregation of chromosomes, and errors in segregation can lead to aneuploidy, contributing to cancer progression.
The researchers found that 2.9% of the 347 patients treated with anti-PD-1 monoclonal antibodies developed subacute onset of neurological complications.
Stage G3b-5 chronic kidney disease independently predicted a nearly 2-fold increased risk recurrence and 3-fold increased risk of progression following transurethral resection.
The six-month cumulative incidence of myocardial infarction was 2.0% and 0.7% in patients with cancer and controls, respectively.
Radical cystectomy is associated with better survival, but findings suggest BPT may produce acceptable oncologic outcomes in appropriately selected patients.
Instilling mitomycin C within 24 hours of TURBT vs after 2 weeks was associated with a 27% lower risk of recurrence.
Researchers find no significant change in overall complication rate from 2010 to 2015, but hospital length of stay and need for transfusion have declined.
In a study, a positive test result was associated with a 5-fold increased risk of recurrent non-muscle invasive bladder cancer.
A new review shows no significant differences in oncologic outcomes, long-term complications, and health-related quality of life between robot-assisted and open radical cystectomy.
The researchers found that 57% of participants expressed interest in learning their secondary germline findings, while 29% and 14%, respectively, were equivocal or disinterested.
Symptomatic recurrence was associated with a nearly 2-fold higher risk of death from the time of recurrence versus surveillance-detected recurrence.
Meta-analysis reveals no significant difference in overall-, disease-specific, and progression-free survival between radical cystectomy and radiation-based, bladder preservation therapy.
After recurrent disease, 5-year overall survival was worse among patients with late recurrence.
The researchers found lower overall survival among patients undergoing robot-assisted radical cystectomy at hospitals performing 10 or fewer procedures during 2010 to 2012.
Of 149 individuals with such tumors who took Keytruda in clinical trials, nearly 40% had a complete or partial remission.
Renal and bladder cancer patients were, respectively, 77% and 73% more likely to report lifetime physical inactivity than controls without cancer.
Patients with a pure variant had significantly lower survival odds than those with pure urothelial carcinoma over a median 6.5 years of follow up.
Research suggests that both cigarettes and e-cigarettes are tied to an increased risk of bladder cancer.
Just 1 in 4 patients diagnosed with metastatic urothelial carcinoma of the bladder survive for a year, according to US national registry data.
By 2014 to 2015, 1 in 3 bladder cancer surgical procedures performed in the United States were robot-assisted.
Researchers find prolonged survival among patients with neuroendocrine muscle-invasive bladder cancer.
Five-year cancer-specific survival rates were 48.1% and 69.6% for PD-L1 positive and negative patients, respectively.
Study finds a higher death risk following radical cystectomy for squamous cell and small cell carcinoma and micropapillary histologic subtypes.
The cumulative incidence of venous thromboembolism following radical cystectomy was nearly 6.7% over 10 years.
Following radical cystectomy for bladder cancer, end-stage renal disease patients are 3-4 times more likely to die from causes other than cancer.
Use of continent diversion procedures peaked in 2008, and has been decreasing since.
Patients smoking 1 or more packs of cigarettes per day had a higher risk of death compared with those who smoked less than 1.
Sensitivity is 90% for BLC compared with 75% for white light cystoscopy.
The protective effect of the diabetes drug metformin among patients who undergo surgery for non-muscle invasive bladder cancer is dose dependent, according to a study.
In a study, 2-year survival rates were 14.4% for whites compared with 6.5% for blacks.
Radical cystectomy is associated with better long-term overall survival than trimodal therapy, new study shows.
Use of the monoclonal antibody was associated with a 27% lower risk of death versus chemotherapy.
Finding contrasts with results of randomized clinical trials.
Nomograms specific to radical cystectomy currently do not exist to aid stratification of a patient's risks for complications.
Survey finds that 46% of radiation oncologists have administered ART to patients with muscle-invasive bladder cancer on at least one occasion.
A neutrophil-to-lymphocyte ratio below 3.09 is associated with significantly longer overall and disease-specific survival.
The drug is indicated for treating patients with locally advanced or metastatic disease that progresses despite platinum-containing chemotherapy.
During a median followup of 3.6 and 3.0 years intravesical recurrence developed in 4 (12.5%) and 59 men (30.1%) with and without androgen suppression therapy, respectively.
In a study, 53.1% of patients had concomitant prostate cancer in radical cystectomy specimens.
ASS1 loss occurs in invasive bladder cancer and is targetable by ADI-PEG 20.
After analyzing new data, the FDA again warns that the diabetes drug may be associated with an increased risk for bladder cancer.
Before and after radical cystectomy, thromboembolic events are common in bladder cancer patients who undergo neoadjuvant chemotherapy.
Low levels of vitamin D in the blood may prevent the cells within the bladder from stimulating an adequate response to abnormal cells.
Predictors of distant recurrences after robot-assisted radical cystectomy were mainly dictated by pathological tumor characteristics.
Based on a small study, investigators report encouraging efficacy and safety.
Increased type I collagen mRNA expression in the extracellular matrix microenvironment is associated with poor progression-free survival.
Patients who underwent a radical cystectomy (RC) developed postoperative infection after a median of 13 days.
Patients with diabetes had a significant 42% increased risk of recurrence of cancer and 79% increased risk of progression.
This approach is associated with a 26% decreased risk of disease recurrence at 15 years compared with alternating therapy with mitomycin C.
Tumors in the dome or urachus confer a better prognosis than those in the lateral wall and base, study finds.
Assay could cut down on cystoscopies, researchers say.
Second cancer was fatal in 55% of the cases studied.
Diabetics taking the drug had a significant 68% decreased risk of grade progression compared with diabetics not on the drug.
Researchers find no difference in 5-year disease-specific survival between multi-disciplinary bladder-sparing approach and radical cystectomy.
During first 24 months, 8.7% of patients with favorable pathological characteristics had progressed.
Women with stage IV bladder cancer have a lower median overall survival rate when compared to men.
About a quarter of older patients deemed too frail for chemo responded to atezolizumab.
Four key lifestyle factors include weight, exercise, no smoking, and limiting alcohol.
Atezolizumab received accelerated FDA approval for patients whose disease has progressed despite platinum-based chemotherapy.
Findings for self-reported leisure-time physical activity of moderate to vigorous intensity.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)